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To MR or Not to MR: Is That the Question?*
Maurice Enriquez-Sarano, MD
Rochester, MinnesotaIn paraphrasing Hamlet, we are approaching, as an
existential question, the performance of cardiac
magnetic resonance (CMR) imaging in the assess-
ment of patients with mitral valve prolapse (MVP)
and mitral regurgitation (MR). Should we ask the
question like Hamlet questioning his worthiness,
and question our worthiness as physicians treating
patients with valve disease based on whether we are
using CMR in our armamentarium?
See page 1037
Delling et al. (1) in this issue of iJACC report 75
patients with MVP in whom CMR was performed
and report morphological characteristics of the
MVP in relation to the severity of the MR. They
describe which morphological variables are inde-
pendently linked to the severity of MR and
underscore the importance of anterior leaflet
length, posterior leaflet displacement, posterior
leaflet thickness, and the presence of a flail as
markers for MR. They go on to conclude on “the
ideal role of MRI [is] as an imaging modality for
assessment of MVP patients with significant
MR.” What is my take on the message of this
paper integrated into the current literature on
mitral valve disease?
Some weaknesses of the study are obvious.
1. The series is small, with 75 patients enrolled
and 71 providing effective data, and has limited
power in providing a full analysis of the deter-
minants of MR severity.
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Division of Cardiovascular Diseases, Mayo Clinic, Rochester,
Minnesota. Dr. Enriquez-Sarano is on the Board of Scientific Advisors,
Valtech, Inc., Tel Aviv, Israel.2. MVP is, as noted by the authors, a heteroge-
neous condition (2). This is exemplified by the
type of prolapse reported in this series: 37
bileaflet MVP and 34 posterior leaflet MVP.
No patient had an isolated anterior leaflet
MVP. There were only 15 flail leaflets, presum-
ably posterior. What variables would have de-
termined MR severity if they had included
patients with flail anterior leaflets? These
patients in whom anterior leaflet length is
usually not considerably increased, and thick-
ness is modest, present usually with very
severe MR. Would the authors then have
reached the conclusion that a shorter anterior
leaflet length predicts more severe MR? Thus,
the picture that we obtain from the present
series is skewed by the distribution of the
patients that it examined. Although I gener-
ally favor statistical analyses that include all
patients, in a disease as heterogeneous as
MVP, it would be preferable to separate the
analysis into specific morphologic subsets,
such as bileaflet MVP, to minimize the bias
introduced by the combination of heteroge-
neous subgroups.
3. The limitations of this population leads to the
presentation, as the main result of the study,
of a truism already well known, which states
that patients with flail leaflets have generally
more severe MR than patients with MVP
without flail leaflet. We do not learn much
here.
4. This study is cross-sectional, noting associa-
tions at one point in time, whereas a causality
link between lesions and MR volume would be
better served by assessing progression of MR
and its association with lesion progression. In
that regard, we have previously noted that new
flail leaflets are associated with marked MR
progression (3).
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1047. The quality control analysis, which I applaud,
provides data that are not very encouraging.
The anterior leaflet length measurement shows
considerable intraobserver and interobserver
variability, and there may be a significant
trend for one observer underestimating the
other one, as shown in Figure 3 of that paper
(1). The results are not much more encour-
aging for valve thickness. This is not surpris-
ing because CMR resolution is currently sub-
optimal in regard to dimensions measured
that are quite small. Although the images
provided by CMR are beautiful when seen
within a very small screen, the ability to
define accurately and reproducibly thicknesses
and lengths of leaflets may be arguable.
. The conclusions about CMR as “an ideal tool
to image MVP and MR” are unproven. Can
we diagnose the valve lesions accurately and
predict better than with echocardiography the
reparability of the mitral valve? The link
between valve morphology by echocardiogra-
phy, transthoracic and transesophageal, and
reparability has been proven repeatedly (4,5),
but not for CMR. The link between echocar-
diographic measurements and outcome has
been proven time and again in multiple stud-
ies (6,7), but not so for CMR. Do I feel that
I provide lesser quality care to our patients
because we do not use CMR for MVP and
MR assessment in routine clinical practice?
Certainly not. Thus, to the question “to MR
or not to MR?,” the answer is obviously no, in
routine clinical practice unless there is no other
way to obtain the necessary information in a
specific patient, which we have not yet en-
countered. However, technical progress and
improved resolution may someday change my
mind on this issue.
Having listed this litany of limitations, why do I
pplaud the authors for producing and the editors
or accepting this paper? One reason contributing
o the importance of the study is MR quantitation,
hich allowed the authors to use regurgitant vol-
me as their end point. I regret not seeing the
alues of the regurgitant volume measured by CMR
n the paper, but the principle is important. To the
uestion “to MR or not to MR?”, I respond
nthusiastically yes if it is in regard to the
uantitation of MR in patients with MVP. Our
bservations that quantitative measures of MR
regurgitant volume and orifice) are essential
redictors of outcome (6) have been confirmed in cindependent prospective studies totaling, with
ur own, more than 1,000 patients followed long
erm (8,9). Whether based on CMR or the more
idely used Doppler echocardiography, the im-
ortant concept for clinical practice and research
s to quantify the MR.
The main reason for my positive reaction to this
tudy relates more to its goal of characterizing the
ink between mitral morphology and volumetric regur-
itation than to its results. After decades of echo-
ardiography, catheterization, and cardiac surgery,
he mitral valve’s normal function and pathological
ysfunction remain very incompletely understood.
hese gaps in knowledge are due, not to lack of
nsights or insufficient desire to uncover the mech-
nisms of disease in mitral valve lesions, but to the
omplexity of the anatomy and of the physiology of
his constantly moving cardiac structure. The mitral
alve is formed by the annulus, 2 asymmetric
eaflets, 2 separate papillary muscles attached to the
entricle, and a multitude of chordae that suspend
he leaflets and are of various thicknesses, positions,
nd attachments. How these multiple structures
nteract dynamically during the cardiac cycle to
aintain mitral competency in systole and patency
n diastole remains mysterious for the most part.
his uncertainty applies particularly to the morpho-
ogic alterations leading to the development of MR,
he aim of the reported study. Our ignorance also
elates to the lack of tools to image and measure the
itral valve completely and dynamically. Attempts
t using 2-dimensional slices to comprehend a
omplex 3-dimensional structure have been labori-
us and crude (10). However, there is hope that
mproved imaging research tools may help us fill
hese gaps of knowledge regarding the mitral valve.
he authors show in this study that some morpho-
ogical characterization of the mitral valve is possi-
le with CMR after having reported with the
ame technique data on MVP characterization
11), papillary muscle characterization (12), and
eft ventricular response to mitral surgery. We
elieve that the development of 3-dimensional
chocardiography that relies on insonation of the
ntire mitral apparatus dynamically throughout
he cardiac cycle is an essential progress in
hysiologic assessment of the mitral valve. Pio-
eering studies in the infancy of 3-dimensional
chocardiography demonstrated the importance
f the mitral annulus saddle shape (13). This
ear, our team reported new physiologic insights
nto the normal mitral annular function and the
ontribution of its dynamics to the maintenance
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1048f mitral competency, and into the pathophysi-
logy of mitral annular dysfunction with MVP
nd ischemic MR (14). These new insights, those
rought by the present study and those that will
nvariably be obtained in the future by high-
esolution imaging, will certainly expand our
nderstanding of how a normal mitral valve
unctions and how a diseased one dysfunctions.
ore important, this new knowledge will un-2005;46:302–9. 2000;102:1400–6.erformed to restore the life expectancy of pa-
ients with mitral valve disease. Although “to MR
r not to MR?” is not the question, I congratulate
elling et al. (1) for their research.
eprint requests and correspondence: Dr. Maurice
nriquez-Sarano, Mayo Clinic, Cardiovascular Diseases,
00 First Street, SW, Rochester, Minnesota 55905-0001.doubtedly improve how mitral valve repair is E-mail: sarano.maurice@mayo.edu.1
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